Immune modulatory effects of alternative interferon alpha-2b and interleukin-2 in patients with metastatic renal cell cancer (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Immune modulatory effects of alternative interferon alpha-2b and interleukin-2 in patients with metastatic renal cell cancer (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 12:A524 1993. Unique Identifier : AIDSLINE ICDB/94694923
Boaziz C; Raymond E; Morere JF; Breau JL; Israel L; Clinique Universitaire de Cancerologie, Hopital Avicenne, 93000; Bobigny, France

Abstract: 20 patients (pts), with metastatic renal cell carcinoma (MRCC), received two induction courses, every 4 wk with interferon alpha 2b (IFN-A) 10 x 106 units/day im day 1-5 followed by continuous iv infusion of interleukin-2 (IL-2) 18 x 10(6) units/day days 8-12. Maintenance therapy at the same doses were administered every 6 wk if response or stabilization. The median follow-up was 10 mo. Four partial responses (20%), 13 stabilizations (65%) and 3 progressive diseases (15%) were observed. The phenotypes of peripheral lymphocytes were analyzed by cytofluorometry. The mean CD4/CD8 ratio, obtained before therapy in pts with MRCC, was compared with CD4/CD8 ratio in 51 pts with other malignant histological types and control pts. The CD4/CD8 ratio was significantly higher in pts with MRCC (2.55) compared to control pts (1.66 chi2 = 17.378). IL-2 therapy induced a decrease of all the lymphocyte subpopulations except CD25+. Four weeks after the completion of each course an elevated level of the lymphocyte count was observed for especially CD4+, CD8+, CD4+CD45RA- and CD16+CD8- cells. After 3 courses of immunotherapy, responding pt showed a CD4/CD8 ratio of 14 (+/- 3.8) compared to 2.8 (+/- 1.44) in nonresponders. Furthermore, the elevation of the CD4/CD8 ratio was prolonged during all the period of response lasting 7-18 mo.

Keywords: Carcinoma, Renal Cell/*DRUG THERAPY/IMMUNOLOGY CD4-CD8 Ratio Human Immunophenotyping *Immunotherapy Interferon-alpha/*ADMINISTRATION & DOSAGE Interleukin-2/*ADMINISTRATION & DOSAGE Kidney Neoplasms/*DRUG THERAPY/IMMUNOLOGY ABSTRACT
940228
M9420828

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .